Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PasterVac THYMO is an oral health supplement developed and manufactured by Dalat Pasteur Vaccines (DAVAC) in Vietnam. Registered as a nutraceutical (thực phẩm bảo vệ sức khỏe), it is marketed for general immune support and strengthening the body's resistance. While the manufacturer does not specify a precise molecular target, the product name strongly suggests the inclusion of thymomodulin, a calf thymus-derived lysate commonly used in Southeast Asia to modulate immune responses by promoting T-lymphocyte maturation and enhancing phagocytic activity. It is intended for individuals with poor immunity or those recovering from illness, rather than as a therapeutic pharmaceutical for a specific disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PasterVac THYMO.